Innate Pharma : Retour des droits de Lumoxiti à AZN
>Innate retourne les droits de Lumoxiti - Innate Pharma communique ce matin sa décision de retourner à son partenaire Astrazeneca les droits commerciaux aux US et en Europe de Lumoxiti, médicament approuvé par la FDA américaine dans le traitement de la leucémie à tricholeucocytes r/r (une maladie rare du sang). A cet effet la société annonce 1/ la prochaine mise en place d’un plan de transition incluant un accord sur les coûts et délais du transfert des droits co...Innate Pharma S.A. is a biopharmaceutical Company developing immunotherapy drugs for cancer and inflammatory diseases. Co. specializes in the development of new monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Also, Co. has three product-candidates resulting from its research platform are being tested in clinical trials; two of these by Co.'s partners, Bristol-Myers Squibb and Novo Nordisk A/S. Co. focuses on immunopharmacology and antibody technology. Co. has a panel of molecular and cellular assays and in vivo models for assessing the pharmacodynamics, the pharmacotoxicology and efficacy of drug candidates.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.